8095.T

The company maintains a debt-to-equity ratio of 0.84, indicating a moderate reliance on debt financing, and a current ratio of 1.24, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, its net cash position is negative after subtracting total debt, signaling potential liquidity constraints. The company's return on equity is 8.07%, which is a measure of profitability relative to shareholders' equity, and its return on assets is 2.9%, indicating the efficiency of asset use in generating profit.

In terms of profitability, the company's operating income of 2.84 billion JPY and net income of 218.6 million JPY reflect its ability to generate earnings after operating expenses and taxes, respectively. These figures should be compared against the industry's preferred metrics and cohort medians to assess relative performance. The company's gross profit of 21.87 billion JPY indicates the amount of money left after subtracting the cost of goods sold, which is a key indicator of operational efficiency.

The company's revenue is primarily derived from its pharmaceutical products, with no specific segments or geographic regions disclosed in the provided data. This lack of segmentation detail makes it difficult to assess the concentration of revenue across different product lines or geographic markets. The company's growth trajectory is not explicitly detailed in the provided data, but its revenue of 62.74 billion JPY and operating cash flow of 3.39 billion JPY suggest a stable financial position.

The company's risk assessment indicates a medium level of liquidity risk and a low level of dilution risk. The key flag of negative net cash after subtracting total debt highlights a potential liquidity issue that could affect the company's ability to meet short-term obligations. The company's capital structure, with long-term debt of 22.65 billion JPY and cash and equivalents of 10.19 billion JPY, suggests a need for careful management of its debt obligations.

Recent events and filings are not detailed in the provided data, which limits the ability to assess the company's recent performance and strategic direction. The company's financial health and strategic initiatives would benefit from a more comprehensive review of its recent disclosures and market activities.